Postoperative complications associated with perioperative sirolimus prior to pediatric cardiac retransplantation.
OBJECTIVE
Sirolimus has been used in pediatric cardiac transplantation for the past decade for chronic renal dysfunction, recurrent rejection, and/or coronary allograft vasculopathy. There has been concern regarding the effect of sirolimus on wound healing and other postoperative complications. To date, the pediatric literature on its use is limited and has not specifically addressed its use in the perioperative period following repeat cardiac transplantation.


METHODS
We compared the patients in our institution who received sirolimus before repeat cardiac transplantation to those in the same era who did not receive sirolimus.


RESULTS
Of the 5 patients in the study group, 5 (100%) developed pleural effusions vs 1 (17%) in the control group (p=0.013). There was no increase in mortality in the sirolimus group, and there were no significant differences in renal dysfunction, serious bacterial infection, rejection, or postoperative length of stay.


CONCLUSIONS
In this small data set, there was a statistically significant increase in pleural effusions in patients on sirolimus. Further study is needed to develop an appropriate strategy to avoid postoperative complications in this patient population.
Baylor College of Medicine, Houston, Texas.
Jason F
JF
Goldberg
Baylor College of Medicine, Houston, Texas.
Aamir
A
Jeewa
Baylor College of Medicine, Houston, Texas.
William J
WJ
Dreyer
Baylor College of Medicine, Houston, Texas.
Gerald J
GJ
Adams
Baylor College of Medicine, Houston, Texas.
Antonio G
AG
Cabrera
Baylor College of Medicine, Houston, Texas.
Jack F
JF
Price
Baylor College of Medicine, Houston, Texas.
Jeffrey S
JS
Heinle
Baylor College of Medicine, Houston, Texas.
Susan W
SW
Denfield
heart transplantation; pediatrics; postoperative complications; sirolimus